Polymer gel to treat TMJ pain

治疗颞下颌关节疼痛的聚合物凝胶

• 批准号: 6741713
• 负责人: Albert Prescott
• 金额: $ 10万
• 依托单位: CRESCENT INNOVATIONS
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2005-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6741713
• 关键词: analgesia; biodegradable product; biomaterial development /preparation; biotechnology; disease /disorder model; disease /therapy duration; female; gel; joint disorder; knee; musculoskeletal disorder therapy; nonhuman therapy evaluation; osteoarthritis; polymers; surgery; swine; temporomandibular joint syndrome

DESCRIPTION: The purpose of this project is to determine if Crescent Innovations polymer gels have application in treating TMJ pain, 7 million Americans suffer pain in the temporomandibular joint (i.e., the jaw joint) each year. The only long term non-invasive therapy for TMJ pain is non-steroidal anti-inflammatories, and they are less than 50% effective. The overall objective of this program is to develop a biologically absorbable polymer gel that may serve as a long-term minimally invasive therapy for treating pain in the temporomandibular joint associated with internal derangement and/or osteoarthritis (ID/OA). Currently the NIH recommends that minimally invasive procedures be used to treat TMJ disorders (TMD). Despite this, there are few minimally invasive therapies available to TMD patients or the doctors who treat them. Biologically absorbable polymer gels are currently used to treat osteoarthritis of the knee. There has been some work performed that suggests these gels would provide a benefit to TMD patients, but the work is limited. If a product of this type were available, it would be one of the only long-term minimally invasive therapies available to TMD sufferers. The primary objective of this Phase I SBIR application is to determine the feasibility of using proprietary Crescent Innovations polymer gels to treat ID/OA TMD. This will lead to a Phase II study, which will determine the long-term efficacy and safety impact of the polymer gel treatment. Therefore, the Specific Aim of this Application is to: Determine if Crescent Innovations enhanced formulations, specifically catering to the unique characteristics of the TM joint, provide superior clinical benefits in an animal model compared to a product used to treat OA of the knee.

描述：该项目的目的是确定新月创新聚合物凝胶是否适用于治疗TMJ疼痛，700万美国人每年在颞下颌关节（即颌关节）遭受疼痛。 TMJ疼痛的唯一长期非侵入性治疗是非甾体抗炎药，效果不到50％。 该程序的总体目的是开发一种具有生物吸收性的聚合物凝胶，该凝胶可能是一种长期的微创疗法，用于治疗与内粘着内皮关节的疼痛，与内部危险和/或骨关节炎相关（ID/OA）。目前，NIH建议使用最小的侵入性程序来治疗TMJ疾病（TMD）。尽管如此，TMD患者或治疗它们的医生几乎没有最低侵入性的疗法。 目前，具有生物吸收性的聚合物凝胶可用于治疗膝盖的骨关节炎。已经进行了一些工作，表明这些凝胶会为TMD患者带来好处，但工作有限。如果有这种类型的产品，它将是TMD患者可用的唯一长期最微创疗法之一。 该阶段I SBIR应用的主要目的是确定使用专有新月创新聚合物凝胶治疗ID/OA TMD的可行性。这将导致II期研究，这将确定聚合物凝胶处理的长期疗效和安全性影响。因此，本申请的具体目的是： 确定新月创新是否增强了配方，特别适合TM关节的独特特征，与用于治疗膝盖OA的产品相比，动物模型中具有较高的临床益处。